Skip to main content
Top
Published in: Radiation Oncology 1/2016

Open Access 01-12-2016 | Research

Establishing stereotactic body radiotherapy with flattening filter free techniques in the treatment of pulmonary lesions - initial experiences from a single institution

Authors: Juliane Rieber, Eric Tonndorf-Martini, Oliver Schramm, Bernhard Rhein, Laila König, Sebastian Adeberg, Eva Meyerhof, Angela Mohr, Jutta Kappes, Hans Hoffmann, Jürgen Debus, Stefan Rieken

Published in: Radiation Oncology | Issue 1/2016

Login to get access

Abstract

Background

Stereotactic body radiotherapy (SBRT) using flattening filter free (FFF)-techniques has been increasingly applied during the last years. However, clinical studies investigating this emerging technique are still rare. Hence, we analyzed toxicity and clinical outcome of pulmonary SBRT with FFF-techniques and performed dosimetric comparison to conventional techniques using flattening filters (FF).

Materials and methods

Between 05/2014 and 06/2015, 56 consecutive patients with 61 pulmonary lesions were treated with SBRT in FFF-mode. Central lesions received 8 × 7.5 Gy delivered to the conformally enclosing 80 %-isodose, while peripheral lesions were treated with 3 × 15 Gy, prescribed to the 65 %-isodose. Early and late toxicity (after 6 months) as well as initial clinical outcomes were evaluated. Furthermore, [deleted] plan quality and efficiency were evaluated by analyzing conformity, beam- on and total treatment delivery times in comparison to plans with FF-dose application.

Results

Median follow-up time was 9.3 months (range 1.5–18.0 months). Early toxicity was low with only 5 patients (8.9 %) reporting CTCAE 2° or higher side-effects. Only one patient (1.8 %) was diagnosed with radiation-induced pneumonitis CTCAE 3°, while 2 (3.6 %) patients suffered from pneumonitis CTCAE 2°. After 6 months, no toxicity greater than CTCAE 2° was reported. 1-year local progression-free survival, distant progression-free survival and overall survival were 92.8 %, 78.0 %, and 94.4 %, respectively. While plan quality was similar for FFF- and FF-plans in respect to conformity (p = 0.275), median beam-on time as well as total treatment time were significantly reduced for SBRT in FFF-mode compared to FF-mode (p ≤ 0.001, p ≤ 0.001).

Conclusions

Patient treatment with SBRT using FFF-techniques is safe and provides promising clinical results with only modest toxicity at significantly increased dose delivery speed.
Literature
1.
go back to reference Haasbeek CJ, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012;23:2743–7.CrossRefPubMed Haasbeek CJ, Palma D, Visser O, Lagerwaard FJ, Slotman B, Senan S. Early-stage lung cancer in elderly patients: a population-based study of changes in treatment patterns and survival in the Netherlands. Ann Oncol. 2012;23:2743–7.CrossRefPubMed
2.
go back to reference Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132:193–9.CrossRefPubMed Raz DJ, Zell JA, Ou SH, Gandara DR, Anton-Culver H, Jablons DM. Natural history of stage I non-small cell lung cancer: implications for early detection. Chest. 2007;132:193–9.CrossRefPubMed
3.
go back to reference Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.CrossRefPubMedPubMedCentral Timmerman R, Paulus R, Galvin J, Michalski J, Straube W, Bradley J, et al. Stereotactic body radiation therapy for inoperable early stage lung cancer. JAMA. 2010;303:1070–6.CrossRefPubMedPubMedCentral
4.
go back to reference Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27:3290–6.CrossRefPubMed Baumann P, Nyman J, Hoyer M, Wennberg B, Gagliardi G, Lax I, et al. Outcome in a prospective phase II trial of medically inoperable stage I non-small-cell lung cancer patients treated with stereotactic body radiotherapy. J Clin Oncol. 2009;27:3290–6.CrossRefPubMed
5.
go back to reference Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B, et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys. 2011;80:1343–9.CrossRefPubMed Bral S, Gevaert T, Linthout N, Versmessen H, Collen C, Engels B, et al. Prospective, risk-adapted strategy of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: results of a Phase II trial. Int J Radiat Oncol Biol Phys. 2011;80:1343–9.CrossRefPubMed
6.
go back to reference Guckenberger M, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013;8:1050–8.CrossRefPubMed Guckenberger M, Allgauer M, Appold S, Dieckmann K, Ernst I, Ganswindt U, et al. Safety and efficacy of stereotactic body radiotherapy for stage 1 non-small-cell lung cancer in routine clinical practice: a patterns-of-care and outcome analysis. J Thorac Oncol. 2013;8:1050–8.CrossRefPubMed
7.
go back to reference Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9:91.CrossRefPubMedPubMedCentral Navarria P, Ascolese AM, Tomatis S, Cozzi L, De Rose F, Mancosu P, et al. Stereotactic body radiotherapy (sbrt) in lung oligometastatic patients: role of local treatments. Radiat Oncol. 2014;9:91.CrossRefPubMedPubMedCentral
8.
go back to reference Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012;75:77–81.CrossRefPubMed Ricardi U, Filippi AR, Guarneri A, Ragona R, Mantovani C, Giglioli F, et al. Stereotactic body radiation therapy for lung metastases. Lung Cancer. 2012;75:77–81.CrossRefPubMed
9.
go back to reference Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol. 2010;5:1091–9.CrossRefPubMed Siva S, MacManus M, Ball D. Stereotactic radiotherapy for pulmonary oligometastases: a systematic review. J Thorac Oncol. 2010;5:1091–9.CrossRefPubMed
10.
go back to reference Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.CrossRefPubMedPubMedCentral Chang JY, Senan S, Paul MA, Mehran RJ, Louie AV, Balter P, et al. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials. Lancet Oncol. 2015;16:630–7.CrossRefPubMedPubMedCentral
11.
go back to reference Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32:3824–30.CrossRefPubMed Iyengar P, Kavanagh BD, Wardak Z, Smith I, Ahn C, Gerber DE, et al. Phase II trial of stereotactic body radiation therapy combined with erlotinib for patients with limited but progressive metastatic non-small-cell lung cancer. J Clin Oncol. 2014;32:3824–30.CrossRefPubMed
12.
go back to reference Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn Jr PA, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807–14.CrossRefPubMedPubMedCentral Weickhardt AJ, Scheier B, Burke JM, Gan G, Lu X, Bunn Jr PA, et al. Local ablative therapy of oligoprogressive disease prolongs disease control by tyrosine kinase inhibitors in oncogene-addicted non-small-cell lung cancer. J Thorac Oncol. 2012;7:1807–14.CrossRefPubMedPubMedCentral
13.
go back to reference Ong CL, Verbakel WF, Dahele M, Cuijpers JP, Slotman BJ, Senan S. Fast arc delivery for stereotactic body radiotherapy of vertebral and lung tumors. Int J Radiat Oncol Biol Phys. 2012;83:e137–143.CrossRefPubMed Ong CL, Verbakel WF, Dahele M, Cuijpers JP, Slotman BJ, Senan S. Fast arc delivery for stereotactic body radiotherapy of vertebral and lung tumors. Int J Radiat Oncol Biol Phys. 2012;83:e137–143.CrossRefPubMed
14.
go back to reference Hoogeman MS, Nuyttens JJ, Levendag PC, Heijmen BJ. Time dependence of intrafraction patient motion assessed by repeat stereoscopic imaging. Int J Radiat Oncol Biol Phys. 2008;70:609–18.CrossRefPubMed Hoogeman MS, Nuyttens JJ, Levendag PC, Heijmen BJ. Time dependence of intrafraction patient motion assessed by repeat stereoscopic imaging. Int J Radiat Oncol Biol Phys. 2008;70:609–18.CrossRefPubMed
15.
go back to reference Kragl G, af Wetterstedt S, Knausl B, Lind M, McCavana P, Knoos T, et al. Dosimetric characteristics of 6 and 10MV unflattened photon beams. Radiother Oncol. 2009;93:141–6.CrossRefPubMed Kragl G, af Wetterstedt S, Knausl B, Lind M, McCavana P, Knoos T, et al. Dosimetric characteristics of 6 and 10MV unflattened photon beams. Radiother Oncol. 2009;93:141–6.CrossRefPubMed
16.
go back to reference Cashmore J. The characterization of unflattened photon beams from a 6 MV linear accelerator. Phys Med Biol. 2008;53:1933–46.CrossRefPubMed Cashmore J. The characterization of unflattened photon beams from a 6 MV linear accelerator. Phys Med Biol. 2008;53:1933–46.CrossRefPubMed
17.
go back to reference Vassiliev ON, Titt U, Ponisch F, Kry SF, Mohan R, Gillin MT. Dosimetric properties of photon beams from a flattening filter free clinical accelerator. Phys Med Biol. 2006;51:1907–17.CrossRefPubMed Vassiliev ON, Titt U, Ponisch F, Kry SF, Mohan R, Gillin MT. Dosimetric properties of photon beams from a flattening filter free clinical accelerator. Phys Med Biol. 2006;51:1907–17.CrossRefPubMed
18.
go back to reference Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190:26–33.CrossRefPubMed Guckenberger M, Andratschke N, Alheit H, Holy R, Moustakis C, Nestle U, et al. Definition of stereotactic body radiotherapy: principles and practice for the treatment of stage I non-small cell lung cancer. Strahlenther Onkol. 2014;190:26–33.CrossRefPubMed
19.
go back to reference Audet C, Poffenbarger BA, Chang P, Jackson PS, Lundahl RE, Ryu SI, et al. Evaluation of volumetric modulated arc therapy for cranial radiosurgery using multiple noncoplanar arcs. Med Phys. 2011;38:5863–72.CrossRefPubMed Audet C, Poffenbarger BA, Chang P, Jackson PS, Lundahl RE, Ryu SI, et al. Evaluation of volumetric modulated arc therapy for cranial radiosurgery using multiple noncoplanar arcs. Med Phys. 2011;38:5863–72.CrossRefPubMed
20.
go back to reference Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. J Neurosurg. 2000;93:219–22.PubMed Paddick I. A simple scoring ratio to index the conformity of radiosurgical treatment plans. J Neurosurg. 2000;93:219–22.PubMed
21.
go back to reference Navarria P, Ascolese AM, Mancosu P, Alongi F, Clerici E, Tozzi A, et al. Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol. 2013;107:414–8.CrossRefPubMed Navarria P, Ascolese AM, Mancosu P, Alongi F, Clerici E, Tozzi A, et al. Volumetric modulated arc therapy with flattening filter free (FFF) beams for stereotactic body radiation therapy (SBRT) in patients with medically inoperable early stage non small cell lung cancer (NSCLC). Radiother Oncol. 2013;107:414–8.CrossRefPubMed
22.
go back to reference Prendergast BM, Fiveash JB, Popple RA, Clark GM, Thomas EM, Minnich DJ, et al. Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy. J Appl Clin Med Phys. 2013;14:4126.PubMed Prendergast BM, Fiveash JB, Popple RA, Clark GM, Thomas EM, Minnich DJ, et al. Flattening filter-free linac improves treatment delivery efficiency in stereotactic body radiation therapy. J Appl Clin Med Phys. 2013;14:4126.PubMed
23.
go back to reference Scorsetti M, Alongi F, Castiglioni S, Clivio A, Fogliata A, Lobefalo F, et al. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol. 2011;6:113.CrossRefPubMedPubMedCentral Scorsetti M, Alongi F, Castiglioni S, Clivio A, Fogliata A, Lobefalo F, et al. Feasibility and early clinical assessment of flattening filter free (FFF) based stereotactic body radiotherapy (SBRT) treatments. Radiat Oncol. 2011;6:113.CrossRefPubMedPubMedCentral
25.
go back to reference Gasic D, Ohlhues L, Brodin NP, Fog LS, Pommer T, Bangsgaard JP, et al. A treatment planning and delivery comparison of volumetric modulated arc therapy with or without flattening filter for gliomas, brain metastases, prostate, head/neck and early stage lung cancer. Acta Oncol. 2014;53:1005–11.CrossRefPubMed Gasic D, Ohlhues L, Brodin NP, Fog LS, Pommer T, Bangsgaard JP, et al. A treatment planning and delivery comparison of volumetric modulated arc therapy with or without flattening filter for gliomas, brain metastases, prostate, head/neck and early stage lung cancer. Acta Oncol. 2014;53:1005–11.CrossRefPubMed
26.
go back to reference Lang S, Shrestha B, Graydon S, Cavelaars F, Linsenmeier C, Hrbacek J, et al. Clinical application of flattening filter free beams for extracranial stereotactic radiotherapy. Radiother Oncol. 2013;106:255–9.CrossRefPubMed Lang S, Shrestha B, Graydon S, Cavelaars F, Linsenmeier C, Hrbacek J, et al. Clinical application of flattening filter free beams for extracranial stereotactic radiotherapy. Radiother Oncol. 2013;106:255–9.CrossRefPubMed
27.
go back to reference Lohse I, Lang S, Hrbacek J, Scheidegger S, Bodis S, Macedo NS, et al. Effect of high dose per pulse flattening filter-free beams on cancer cell survival. Radiother Oncol. 2011;101:226–32.CrossRefPubMed Lohse I, Lang S, Hrbacek J, Scheidegger S, Bodis S, Macedo NS, et al. Effect of high dose per pulse flattening filter-free beams on cancer cell survival. Radiother Oncol. 2011;101:226–32.CrossRefPubMed
28.
go back to reference Prendergast BM, Dobelbower MC, Bonner JA, Popple RA, Baden CJ, Minnich DJ, et al. Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. Radiat Oncol. 2013;8:273.CrossRefPubMedPubMedCentral Prendergast BM, Dobelbower MC, Bonner JA, Popple RA, Baden CJ, Minnich DJ, et al. Stereotactic body radiation therapy (SBRT) for lung malignancies: preliminary toxicity results using a flattening filter-free linear accelerator operating at 2400 monitor units per minute. Radiat Oncol. 2013;8:273.CrossRefPubMedPubMedCentral
29.
go back to reference Sørensen BS, Vestergaard A, Overgaard J, Præstegaard LH. Dependence of cell survival on instantaneous dose rate of a linear accelerator. Radiother Oncol. 2011;101:223–5.CrossRefPubMed Sørensen BS, Vestergaard A, Overgaard J, Præstegaard LH. Dependence of cell survival on instantaneous dose rate of a linear accelerator. Radiother Oncol. 2011;101:223–5.CrossRefPubMed
30.
go back to reference Karan T, Moiseenko V, Gill B, Horwood R, Kyle A, Minchinton AI. Radiobiological effects of altering dose rate in filter-free photon beams. Phys Med Biol. 2013;58:1075.CrossRefPubMed Karan T, Moiseenko V, Gill B, Horwood R, Kyle A, Minchinton AI. Radiobiological effects of altering dose rate in filter-free photon beams. Phys Med Biol. 2013;58:1075.CrossRefPubMed
31.
go back to reference King RB, Hyland WB, Cole AJ, Butterworth KT, McMahon SJ, Redmond KM, et al. An in vitro study of the radiobiological effects of flattening filter free radiotherapy treatments. Phys Med Biol. 2013;58:N83.CrossRefPubMed King RB, Hyland WB, Cole AJ, Butterworth KT, McMahon SJ, Redmond KM, et al. An in vitro study of the radiobiological effects of flattening filter free radiotherapy treatments. Phys Med Biol. 2013;58:N83.CrossRefPubMed
32.
go back to reference Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.CrossRefPubMed Timmerman R, McGarry R, Yiannoutsos C, Papiez L, Tudor K, DeLuca J, et al. Excessive toxicity when treating central tumors in a phase II study of stereotactic body radiation therapy for medically inoperable early-stage lung cancer. J Clin Oncol. 2006;24:4833–9.CrossRefPubMed
33.
go back to reference Kragl G, Baier F, Lutz S, Albrich D, Dalaryd M, Kroupa B, et al. Flattening filter free beams in SBRT and IMRT: Dosimetric assessment of peripheral doses. Z Med Phys. 2011;21:91–101.CrossRefPubMed Kragl G, Baier F, Lutz S, Albrich D, Dalaryd M, Kroupa B, et al. Flattening filter free beams in SBRT and IMRT: Dosimetric assessment of peripheral doses. Z Med Phys. 2011;21:91–101.CrossRefPubMed
34.
go back to reference Cashmore J, Ramtohul M, Ford D. Lowering whole-body radiation doses in pediatric intensity-modulated radiotherapy through the use of unflattened photon beams. Int J Radiat Oncol Biol Phys. 2011;80:1220–7.CrossRefPubMed Cashmore J, Ramtohul M, Ford D. Lowering whole-body radiation doses in pediatric intensity-modulated radiotherapy through the use of unflattened photon beams. Int J Radiat Oncol Biol Phys. 2011;80:1220–7.CrossRefPubMed
Metadata
Title
Establishing stereotactic body radiotherapy with flattening filter free techniques in the treatment of pulmonary lesions - initial experiences from a single institution
Authors
Juliane Rieber
Eric Tonndorf-Martini
Oliver Schramm
Bernhard Rhein
Laila König
Sebastian Adeberg
Eva Meyerhof
Angela Mohr
Jutta Kappes
Hans Hoffmann
Jürgen Debus
Stefan Rieken
Publication date
01-12-2016
Publisher
BioMed Central
Published in
Radiation Oncology / Issue 1/2016
Electronic ISSN: 1748-717X
DOI
https://doi.org/10.1186/s13014-016-0648-0

Other articles of this Issue 1/2016

Radiation Oncology 1/2016 Go to the issue